These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 2621579)

  • 1. Enantioselective aspects of the disposition of dl-threo-methylphenidate after the administration of a sustained-release formulation to children with attention deficit-hyperactivity disorder.
    Hubbard JW; Srinivas NR; Quinn D; Midha KK
    J Pharm Sci; 1989 Nov; 78(11):944-7. PubMed ID: 2621579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enantioselective pharmacokinetics and pharmacodynamics of dl-threo-methylphenidate in children with attention deficit hyperactivity disorder.
    Srinivas NR; Hubbard JW; Quinn D; Midha KK
    Clin Pharmacol Ther; 1992 Nov; 52(5):561-8. PubMed ID: 1424430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system.
    Heal DJ; Pierce DM
    CNS Drugs; 2006; 20(9):713-38. PubMed ID: 16953648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereoselective disposition of methylphenidate in children with attention-deficit disorder.
    Srinivas NR; Quinn D; Hubbard JW; Midha KK
    J Pharmacol Exp Ther; 1987 Apr; 241(1):300-6. PubMed ID: 3572792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative pharmacodynamics and plasma concentrations of d-threo-methylphenidate hydrochloride after single doses of d-threo-methylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in a double-blind, placebo-controlled, crossover laboratory school study in children with attention-deficit/hyperactivity disorder.
    Quinn D; Wigal S; Swanson J; Hirsch S; Ottolini Y; Dariani M; Roffman M; Zeldis J; Cooper T
    J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1422-9. PubMed ID: 15502602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-Dose Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate Formulation, in Healthy Adults and in Adolescents and Children with Attention-Deficit/Hyperactivity Disorder.
    Childress A; Mehrotra S; Gobburu J; McLean A; DeSousa NJ; Incledon B
    J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):10-18. PubMed ID: 29039979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).
    Swanson JM; Wigal SB; Wigal T; Sonuga-Barke E; Greenhill LL; Biederman J; Kollins S; Nguyen AS; DeCory HH; Hirshe Dirksen SJ; Hatch SJ;
    Pediatrics; 2004 Mar; 113(3 Pt 1):e206-16. PubMed ID: 14993578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extensive and enantioselective presystemic metabolism of dl-threo-methylphenidate in humans.
    Srinivas NR; Hubbard JW; Quinn D; Korchinski ED; Midha KK
    Prog Neuropsychopharmacol Biol Psychiatry; 1991; 15(2):213-20. PubMed ID: 1871323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of methylphenidate and ritalinic acid in plasma correlations with exhaled breath and oral fluid in healthy volunteers.
    Arvidsson M; Dahl ML; Beck O; Ackehed G; Nordin K; Rosenborg S
    Eur J Clin Pharmacol; 2020 Feb; 76(2):229-237. PubMed ID: 31786618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Single-Dose, Single-Period Pharmacokinetic Assessment of an Extended-Release Orally Disintegrating Tablet of Methylphenidate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
    Childress A; Newcorn J; Stark JG; McMahen R; Tengler M; Sikes C
    J Child Adolesc Psychopharmacol; 2016 Aug; 26(6):505-12. PubMed ID: 27228207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended-release methylphenidate (Ritalin LA).
    Lyseng-Williamson KA; Keating GM
    Drugs; 2002; 62(15):2251-9; discussion 2260-1. PubMed ID: 12381228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-dose pharmacokinetics of multilayer-release methylphenidate and immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder.
    Quinn D; Bode T; Reiz JL; Donnelly GA; Darke AC
    J Clin Pharmacol; 2007 Jun; 47(6):760-6. PubMed ID: 17395894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: a comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline.
    Pelham WE; Greenslade KE; Vodde-Hamilton M; Murphy DA; Greenstein JJ; Gnagy EM; Guthrie KJ; Hoover MD; Dahl RE
    Pediatrics; 1990 Aug; 86(2):226-37. PubMed ID: 2196522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
    Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
    Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Similar bioavailability of dexmethylphenidate extended (bimodal) release, dexmethyl-phenidate immediate release and racemic methylphenidate extended (bimodal) release formulations in man.
    Tuerck D; Wang Y; Maboudian M; Wang Y; Sedek G; Pommier F; Appel-Dingemanse S
    Int J Clin Pharmacol Ther; 2007 Dec; 45(12):662-8. PubMed ID: 18184535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does chirality matter? pharmacodynamics of enantiomers of methylphenidate in patients with attention-deficit/hyperactivity disorder.
    Quinn D
    J Clin Psychopharmacol; 2008 Jun; 28(3 Suppl 2):S62-6. PubMed ID: 18480679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single- and multiple-dose pharmacokinetics of methylphenidate administered as methylphenidate transdermal system or osmotic-release oral system methylphenidate to children and adolescents with attention deficit hyperactivity disorder.
    Pierce D; Katic A; Buckwalter M; Webster K
    J Clin Psychopharmacol; 2010 Oct; 30(5):554-64. PubMed ID: 20814325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-dose pharmacokinetics of NWP06, an extended-release methylphenidate suspension, in children and adolescents with ADHD.
    Childress AC; Sallee FR; Berry SA
    Postgrad Med; 2011 Sep; 123(5):80-8. PubMed ID: 21904089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methylphenidate (OROS formulation).
    Keating GM; McClellan K; Jarvis B
    CNS Drugs; 2001; 15(6):495-500; discussion 501-3. PubMed ID: 11524026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dexmethylphenidate extended-release capsules for the treatment of attention deficit hyperactivity disorder.
    Kowalik S; Minami H; Silva R
    Expert Opin Pharmacother; 2006 Dec; 7(18):2547-57. PubMed ID: 17150008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.